Touchlight News and Resources

Touchlight, an innovation-focused Contract Development and Manufacturing Organisation (CDMO), has announced GMP certification of its facility in Hampton, UK. The achievement positions the company as the first globally to gain regulatory approval for synthetic DNA Active Pharmaceutical Ingredient (API) production,

Touchlight, a contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, has announced the clinical supply of its proprietary dbDNA™ technology to the University of Nottingham. This partnership supports the university’s research and development efforts for a next-generation

Touchlight, an innovation-driven CDMO, has entered into a license agreement with GSK, a leader in biopharmaceutical innovation. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.

LenioBio, a biotech company pioneering cell-free protein production, has entered into a supply agreement with Touchlight, privately-owned CDMO based in London. The collaboration aims to harness Touchlight’s rapid enzymatic doggybone DNA (dbDNA) to accelerate vaccine development within LenioBio’s CEPI-funded project. LenioBio’s

Touchlight, a Contract Development and Manufacturing Organisation (CDMO) based in the UK, has announced a collaboration with the University of Liverpool. The partnership aims to utilise Touchlight’s proprietary doggybone DNA (dbDNA) technology in the development of a personalised DNA vaccine